M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

Pegcetacoplan has been approved for the treatment of C3 glomerulopathy or primary immune complex membranoproliferative ...

Waltham, Massachusetts Wednesday, July 30, 2025, 11:00 Hrs [IST] ...

Unlike some German brands, French carmaker Citroen leads from the front and is not afraid to mix it up when it comes to design.

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

C3 Bullion, a pioneer in next-generation gold investment solutions, has launched its India operations, bringing its flagship ...

Finance Minister Ros Bates was informed of the Callide Power Station explosion just hours after the April 4 incident, new ...

C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

The FDA approved pegcetacoplan (EMPAVELI; Apellis Pharmaceuticals) as the first treatment for patients aged 12 and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...